查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591969

特發性肺纖維化市場：按藥物類型、分銷管道和最終用戶分類 - 全球預測 2025-2030

Idiopathic Pulmonary Fibrosis Market by Drug Type (Nintedanib, Pirfenidone), Distribution Channel (Offline, Online), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年特發性肺纖維化市場價值為34.6億美元，預計2024年將達到36.5億美元，複合年成長率為5.47%，到2030年將達到50.3億美元。

特發性肺纖維化（IPF）是進行性慢性肺部疾病，其特徵是肺組織出現不明原因的疤痕，導致嚴重的呼吸道疾病。就市場研究範圍而言，特發性肺纖維化（IPF）的主要定義是其在世界老齡化人口中日益流行，增加了對有效治療方案和患者管理解決方案的需求。由於缺乏明確的治療方法，強調了解決 IPF 的必要性，因此必須專注於藥物開發和治療方法強化。最終用戶主要是專注於創新藥物發現、先進診斷工具和綜合護理策略的製藥公司、醫療保健提供者和研究機構。影響 IPF 市場的主要成長要素包括基因組和生物技術的進步、政府透過資金和優惠政策提供的支持，以及倡導早期診斷和治療的提高認知活動。最新的潛在商機在於個人化醫療和生技藥品，它們有望透過解決個體的遺傳和分子特徵來徹底改變 IPF 治療。鼓勵企業投資尖端合作研究，利用人工智慧加速藥物發現和開發。儘管有這些機遇，挑戰仍然存在，包括高昂的治療成本、嚴格的監管要求以及 IPF 的複雜性使配方變得複雜。此外，對病理學的有限了解也是一個主要障礙。市場相關人員應致力於透過專注於基因編輯技術、液態切片等改進的診斷方法以及以患者為中心的護理模式等創新領域來發展業務。對市場性質的討論表明，持續的研發和策略聯盟正在推動競爭格局的發展，以加強產品平臺。強調全人治療解決方案和促進全面的患者支援服務是有效引導市場並確保競爭優勢和患者福祉的關鍵策略。

主要市場統計
基準年[2023] 34.6億美元
預測年份 [2024] 36.5億美元
預測年份 [2030] 50.3億美元
複合年成長率（%） 5.47%

市場動態：快速發展的特發性肺纖維化市場的關鍵市場洞察

特發性肺纖維化市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 特發性肺纖維化盛行率增加
    • 醫療和診斷技術的進步
  • 市場限制因素
    • 治療/治療費用高
  • 市場機會
    • 精準醫療創新與標靶治療開發
    • 特發性肺纖維化的罕見疾病認定和 IPF 治療藥物開發的獎勵
  • 市場挑戰
    • 關於 IPF 治療的副作用和潛在風險的治療問題

波特五力：駕馭特發性纖維化市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解特發性肺纖維化市場的外部影響

外部宏觀環境因素在塑造特發性肺纖維化市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解特發性肺纖維化市場的競爭格局

對特發性肺纖維化市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣特特發性肺纖維化市場供應商的績效評估

FPNV 定位矩陣是評估特發性肺纖維化市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製特發性肺纖維化市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對特發性肺纖維化市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 特發性肺纖維化盛行率增加
      • 醫療和診斷技術的進步
    • 抑制因素
      • 治療費用上漲
    • 機會
      • 精準醫學創新與標靶治療的發展
      • 特發性肺纖維化的罕見疾病認定和 IPF 治療藥物開發的獎勵
    • 任務
      • 對 IPF 治療副作用和潛在風險的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章特發性肺纖維化市場藥物按類型

  • 尼達尼布
  • Pirfenidone

第7章特發性肺纖維化市場：按通路

  • 離線
  • 線上

第 8 章特發性肺纖維化市場：依最終用戶分類

  • 門診手術中心
  • 居家護理設施
  • 醫院/診所

第9章美洲特發性肺纖維化市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區特發性肺纖維化市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲特發性肺纖維化市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Algernon Pharmaceuticals Inc.
  • Alkem Laboratories Ltd.
  • AstraZeneca PLC
  • Avalyn Pharma Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Camber Pharmaceuticals, Inc. by Hetero Labs Limited
  • Chemo Healthcare Pvt. Ltd.
  • Cipla Limited
  • Dr Reddy's Laboratories Ltd.
  • FibroGen, Inc.
  • Galapagos NV
  • Glenmark Pharmaceuticals Ltd.
  • GNI Group Ltd.
  • Horizon Therapeutics PLC by Amgen Inc.
  • Lupin Ltd.
  • MediciNova, Inc.
  • Merck & Co.
  • Mission Therapeutics
  • MSN Laboratories Private Limited
  • Sandoz International GmbH
  • Sanify Healthcare Private Limited
  • Shionogi & Co., Ltd.
  • Teva Pharmaceuticals, Inc.
Product Code: MRR-2A0283E25610

The Idiopathic Pulmonary Fibrosis Market was valued at USD 3.46 billion in 2023, expected to reach USD 3.65 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 5.03 billion by 2030.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and chronic lung condition characterized by unexplained scarring of lung tissue, leading to severe respiratory issues. In the scope of market research, IPF is defined primarily by its growing incidence rate among the global aging population, thus prompting an increased necessity for effective treatment options and patient management solutions. The necessity for addressing IPF is underscored by the lack of definitive curative therapies, making it imperative to focus on drug development and therapy enhancement. Application and end-use scope principally encompass pharmaceutical companies, healthcare providers, and research institutions focusing on innovative drug discovery, advanced diagnostic tools, and comprehensive care strategies. Key growth factors influencing the IPF market include advancements in genomics and biotechnology, governmental support through funding and favorable policies, and increasing awareness initiatives advocating for early diagnosis and treatment. The latest potential opportunities lie in personalized medicine and biologics, which promise to revolutionize IPF treatment by catering to individual genetic and molecular profiles. Companies are recommended to invest in cutting-edge research collaborations and leverage artificial intelligence for accelerated drug discovery and development. Despite these opportunities, challenges persist such as high treatment costs, stringent regulatory requirements, and the complex nature of IPF which complicates drug formulation. Moreover, the limited understanding of the disease pathogenesis poses significant hurdles. Market players should focus on areas of innovation such as gene editing technologies, improved diagnostic methodologies like liquid biopsy, and patient-centric care models for business growth. Insights into the market's nature suggest a competitive landscape, driven by continuous R&D and strategic partnerships to enhance product pipelines. Emphasizing holistic treatment solutions and fostering comprehensive patient support services will be crucial strategies to navigate the market effectively, ensuring both competitive advantage and patient welfare.

KEY MARKET STATISTICS
Base Year [2023] USD 3.46 billion
Estimated Year [2024] USD 3.65 billion
Forecast Year [2030] USD 5.03 billion
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Idiopathic Pulmonary Fibrosis Market

The Idiopathic Pulmonary Fibrosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of idiopathic pulmonary fibrosis
    • Advancements in the medical and diagnostic technology
  • Market Restraints
    • High cost of therapies and treatments
  • Market Opportunities
    • Innovations in the precision medicine and development of targeted therapies
    • Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
  • Market Challenges
    • Concerns associated with side-effects and potential risk of IPF treatment

Porter's Five Forces: A Strategic Tool for Navigating the Idiopathic Pulmonary Fibrosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Idiopathic Pulmonary Fibrosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Idiopathic Pulmonary Fibrosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Idiopathic Pulmonary Fibrosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Idiopathic Pulmonary Fibrosis Market

A detailed market share analysis in the Idiopathic Pulmonary Fibrosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Idiopathic Pulmonary Fibrosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Idiopathic Pulmonary Fibrosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Idiopathic Pulmonary Fibrosis Market

A strategic analysis of the Idiopathic Pulmonary Fibrosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Idiopathic Pulmonary Fibrosis Market, highlighting leading vendors and their innovative profiles. These include Algernon Pharmaceuticals Inc., Alkem Laboratories Ltd., AstraZeneca PLC, Avalyn Pharma Inc., Biogen, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Camber Pharmaceuticals, Inc. by Hetero Labs Limited, Chemo Healthcare Pvt. Ltd., Cipla Limited, Dr Reddy's Laboratories Ltd., FibroGen, Inc., Galapagos NV, Glenmark Pharmaceuticals Ltd., GNI Group Ltd., Horizon Therapeutics PLC by Amgen Inc., Lupin Ltd., MediciNova, Inc., Merck & Co., Mission Therapeutics, MSN Laboratories Private Limited, Sandoz International GmbH, Sanify Healthcare Private Limited, Shionogi & Co., Ltd., and Teva Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Idiopathic Pulmonary Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Nintedanib and Pirfenidone.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Home Care Facilities, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of idiopathic pulmonary fibrosis
      • 5.1.1.2. Advancements in the medical and diagnostic technology
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapies and treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in the precision medicine and development of targeted therapies
      • 5.1.3.2. Designation of idiopathic pulmonary fibrosis as orphan disease and incentives to develop IPF drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with side-effects and potential risk of IPF treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Idiopathic Pulmonary Fibrosis Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Nintedanib
  • 6.3. Pirfenidone

7. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Offline
  • 7.3. Online

8. Idiopathic Pulmonary Fibrosis Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Home Care Facilities
  • 8.4. Hospitals & Clinics

9. Americas Idiopathic Pulmonary Fibrosis Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Idiopathic Pulmonary Fibrosis Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Algernon Pharmaceuticals Inc.
  • 2. Alkem Laboratories Ltd.
  • 3. AstraZeneca PLC
  • 4. Avalyn Pharma Inc.
  • 5. Biogen, Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Bristol Myers Squibb
  • 8. Camber Pharmaceuticals, Inc. by Hetero Labs Limited
  • 9. Chemo Healthcare Pvt. Ltd.
  • 10. Cipla Limited
  • 11. Dr Reddy's Laboratories Ltd.
  • 12. FibroGen, Inc.
  • 13. Galapagos NV
  • 14. Glenmark Pharmaceuticals Ltd.
  • 15. GNI Group Ltd.
  • 16. Horizon Therapeutics PLC by Amgen Inc.
  • 17. Lupin Ltd.
  • 18. MediciNova, Inc.
  • 19. Merck & Co.
  • 20. Mission Therapeutics
  • 21. MSN Laboratories Private Limited
  • 22. Sandoz International GmbH
  • 23. Sanify Healthcare Private Limited
  • 24. Shionogi & Co., Ltd.
  • 25. Teva Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. IDIOPATHIC PULMONARY FIBROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023